Hepion Pharmaceuticals, Inc.
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.
On August 6, 2024, John Brancaccio, the Company’s executive chairman was appointed the interim Chief Executive Officer and interim Chief Financial Officer of the Company.
On August 5, 2024, John Cavan, the interim Chief Executive Officer and Chief Financial Officer of Hepion Pharmaceuticals, Inc. (the “Company”) left the Company for personal reasons.
Extracted from this filing and checked against the source text.
John Brancaccio was appointed as interim Chief Executive Officer and interim Chief Financial Officer at Hepion Pharmaceuticals, Inc..
On August 6, 2024, John Brancaccio, the Company’s executive chairman was appointed the interim Chief Executive Officer and interim Chief Financial Officer of the Company.View on SEC.gov
John Cavan departed as interim Chief Executive Officer and Chief Financial Officer at Hepion Pharmaceuticals, Inc..
On August 5, 2024, John Cavan, the interim Chief Executive Officer and Chief Financial Officer of Hepion Pharmaceuticals, Inc. (the “Company”) left the Company for personal reasons.View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.